First Day on Retatrutide: What to Expect and How to Start Safely

Your first day on retatrutide marks the beginning of a closely supervised treatment journey. Retatrutide (LY3437943) is an investigational triple incretin receptor agonist being evaluated in clinical trials for obesity and type 2 diabetes. It has not yet received MHRA or EMA marketing authorisation and must only be used within a registered clinical trial under qualified medical oversight. This article explains what to expect on day one, how the drug works, which side effects are most common in the early stages, and how to manage the days that follow, so you can approach treatment feeling informed and prepared.

What to Expect on Your First Day Taking Retatrutide

On your first day, retatrutide is administered by subcutaneous injection in a supervised clinical setting, with no dramatic physical changes expected; mild nausea may occur within the first few hours.

Starting a new medication can feel both hopeful and uncertain, and your first day on retatrutide is no exception. Retatrutide (also known as LY3437943) is an investigational injectable medication currently being evaluated in registered clinical trials for the management of obesity and type 2 diabetes. It is important to understand that retatrutide has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA).^[3][4] At the time of writing, no UK Early Access to Medicines Scheme (EAMS) approval is in place for retatrutide; it should therefore only be taken within a registered clinical trial under the direct oversight of a qualified clinical team. You should not attempt to obtain retatrutide from online pharmacies, compounding services, or any unregulated source.

On your first day, the injection will typically be administered by a trial nurse or clinician in a supervised clinical setting. Self-injection at home is only permitted after you have received full training and your investigator has confirmed you are ready to do so. The injection is subcutaneous, given under the skin, usually in the abdomen, thigh, or upper arm. Based on phase 2 clinical trial data (Jastreboff et al., NEJM 2023), the starting dose has been low, with a gradual, pre-specified dose-escalation schedule over subsequent weeks to improve tolerability.

Physically, you may not notice dramatic changes on day one. Meaningful changes in weight or blood glucose develop over weeks of treatment; some people notice early reductions in appetite or modest glycaemic effects after initial doses, but these vary between individuals. Some people also report mild nausea within the first few hours following the injection. These early sensations are generally expected and relate to the drug's mechanism of action.

If you are taking insulin or a sulfonylurea alongside retatrutide, be aware of the signs of hypoglycaemia (low blood sugar), including shakiness, sweating, confusion, and palpitations, and discuss a management plan with your clinical team before your first dose.

Retatrutide is not recommended during pregnancy or breastfeeding. If you are of childbearing potential, your trial team will advise on effective contraception. Inform your team immediately if you become pregnant or are planning a pregnancy.

Practical steps for day one:

• Keep a symptom diary from the outset

• Stay well hydrated throughout the day

• Avoid large, heavy, or high-fat meals immediately after your injection, in line with general guidance for GLP-1-based therapies

• Have your healthcare team's and trial team's contact details readily available

• If you experience urgent or worsening symptoms, call NHS 111 for advice; call 999 or go to your nearest emergency department (A and E) for severe symptoms such as persistent vomiting, severe abdominal pain, or signs of dehydration

Report any suspected side effects to your trial team as the primary route, as instructed in your participant information sheet. You may also report suspected side effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; note that in a clinical trial, your trial team is responsible for formal adverse event reporting to the sponsor and regulator.

How Retatrutide Works in the Body

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, creating a synergistic effect on appetite suppression, caloric intake, and energy expenditure that distinguishes it from currently authorised therapies.

Retatrutide represents a novel class of medication known as a triple incretin receptor agonist. Unlike earlier agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP and GLP-1 receptor agonist), retatrutide is designed to simultaneously activate three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.^[7][8] This triple-action mechanism distinguishes it from currently authorised therapies and is thought to underpin its potentially greater efficacy in weight reduction, though this remains under investigation.

Each receptor plays a specific physiological role:

• GLP-1 receptor activation slows gastric emptying, reduces appetite, and stimulates insulin secretion in a glucose-dependent manner, thereby helping to lower blood sugar levels without causing hypoglycaemia in isolation.^[7][11]

• GIP receptor activation may enhance insulin release and improve fat metabolism, complementing the GLP-1 pathway.

• Glucagon receptor activation may increase energy expenditure and raises hepatic glucose output; human data on the energy expenditure effect remain limited.^[1][8] In early studies, retatrutide has also been associated with reductions in liver fat, though the precise mechanisms and long-term significance of this finding remain under investigation.^[6][19]

The combined stimulation of these three pathways is intended to create a synergistic effect on appetite suppression, caloric intake reduction, and metabolic rate. Because glucagon receptor activation can raise blood glucose in isolation, the simultaneous GLP-1 and GIP stimulation is intended to help maintain glycaemic balance; however, the full safety profile of this combination is still being evaluated in ongoing trials, which is one reason why retatrutide must only be used under close medical supervision.

In a phase 2 randomised controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving the highest doses of retatrutide achieved a mean weight reduction of approximately 17 to 24% of body weight over 48 weeks, depending on dose. These findings are investigational; phase 3 trials are ongoing and regulatory review has not yet been completed. Long-term safety, including cardiovascular outcomes, has not yet been established.

Common Side Effects in the Early Stages of Treatment

The most common early side effects are gastrointestinal, particularly nausea after injection; these are generally mild to moderate and tend to improve as the body adjusts during the gradual dose-escalation schedule.

As with other incretin-based therapies, the most frequently reported side effects of retatrutide, particularly in the early stages of treatment, are gastrointestinal in nature. These effects are largely attributable to the drug's action on gastric motility and appetite-regulating pathways. Understanding what is typical can help you distinguish between expected, manageable symptoms and those that require prompt medical attention.

The most commonly reported early side effects include:

• Nausea, often the most prevalent complaint, particularly in the hours following injection; eating small, low-fat meals and staying hydrated can help

• Vomiting, less common but possible, especially if dietary advice is not followed

• Diarrhoea or constipation, as changes in bowel habit are frequently reported during dose initiation

• Reduced appetite, which, while therapeutically desirable, can occasionally lead to insufficient caloric intake if meals are skipped entirely

• Injection site reactions, such as mild redness, bruising, or discomfort at the injection site

• Fatigue or dizziness, as some individuals feel lightheaded, particularly if food intake is significantly reduced

These side effects are generally mild to moderate in severity and tend to improve as the body adjusts to the medication over the first few weeks. The gradual dose-escalation protocol used in clinical trials is specifically designed to minimise their impact.^[1][2]

Hypoglycaemia: If you are also taking insulin or a sulfonylurea, retatrutide may increase the risk of low blood sugar. Recognise the symptoms (shakiness, sweating, confusion, palpitations) and follow your clinical team's guidance on managing a hypoglycaemic episode, typically by taking a fast-acting carbohydrate and seeking a medication review.

Dehydration and kidney function: If you experience prolonged vomiting or diarrhoea and are unable to keep fluids down, or notice reduced urine output or signs of severe dehydration, seek urgent medical advice. Your clinical team can advise on 'sick day rules' for any other medicines you take, such as certain blood pressure or diabetes medications, to reduce the risk of kidney problems during illness.

Biliary and gallbladder symptoms: As a potential class effect observed with GLP-1 receptor agonists, there is a possible signal for gallbladder-related problems; retatrutide-specific data are limited.^[12][13] Seek urgent medical assessment if you develop right upper quadrant or upper abdominal pain, fever, or yellowing of the skin or eyes (jaundice).

Pancreatitis: Seek urgent medical advice if you experience severe or persistent abdominal pain, particularly if it radiates to the back. There is no confirmed causal link between retatrutide and pancreatitis at this stage, but vigilance is warranted given the drug's pharmacological class.

Allergic reactions: Seek emergency help (call 999) if you develop signs of a serious allergic reaction, such as swelling of the face, lips, or throat, difficulty breathing, or a widespread rash.

For urgent concerns, contact NHS 111. For severe or worsening symptoms, call 999 or attend your nearest emergency department (A and E). Report all suspected adverse reactions to your trial team as the primary route; your trial team is responsible for formal reporting to the sponsor and regulator.

Practical Tips for Starting Retatrutide Safely

Eat a light, low-fat meal before your injection, rotate injection sites, stay well hydrated, and inform your GP and all treating clinicians that you are commencing retatrutide within a clinical trial.

Preparation and informed self-management are key to a safe and positive experience on your first day on retatrutide. The following practical guidance applies to participants in a clinical trial.

Before your first injection:

• Ensure you have received full training on subcutaneous injection technique from a qualified healthcare professional before attempting self-injection

• Store and handle retatrutide exactly as stated on the study pack label and per your investigator's instructions; do not use the medication if storage conditions were not maintained as directed

• Choose a consistent day of the week for your weekly injection to help establish a routine

• Inform your GP and any other treating clinicians that you are commencing retatrutide, particularly if you take other medications that may interact

• Use only medication supplied by the trial or sponsor; do not obtain retatrutide from online pharmacies, compounding services, or any unregulated source

On the day of your injection:

• Eat a light, low-fat meal beforehand rather than a large or greasy one, as this may worsen nausea

• Inject at a time of day that suits your schedule; many people prefer mornings so that any early reactions can be monitored while awake

• Rotate injection sites to reduce localised skin reactions

• Remain well hydrated throughout the day

Sharps safety:

• Dispose of used needles and syringes immediately in the sharps bin provided by your trial team

• Never share needles, syringes, or injection pens with anyone else

• Follow your trial team's instructions for the collection or disposal of full sharps bins; your local NHS trust or council may also offer a sharps disposal service

Ongoing safety considerations:

• Do not adjust your dose without medical guidance

• If you are taking insulin or other glucose-lowering agents, your clinician may need to review and adjust these to reduce the risk of hypoglycaemia; if you drive and are at risk of hypoglycaemia, check DVLA guidance on fitness to drive

• Some medicines, including certain oral contraceptives, may be affected by delayed gastric emptying; check with your trial team whether any of your regular medicines could be affected

• Limit alcohol, particularly in the early weeks of treatment, as it may worsen nausea and dizziness

• If you experience significant vomiting or diarrhoea, discuss sick day rules for any other medicines you take with your clinical team

• Keep a written or digital log of any symptoms to share with your healthcare team at your next appointment

In line with NICE guidance on shared decision-making, your healthcare team should have discussed the potential benefits, risks, and alternatives with you before commencing treatment.

What Happens After the First Few Days on Retatrutide

Gastrointestinal side effects often begin to settle within a few days; meaningful appetite reduction typically emerges during the first week, with measurable weight changes usually apparent from weeks four to eight onwards.

The days immediately following your first retatrutide injection are an important period of adjustment. For most people, any gastrointestinal side effects experienced on day one will often begin to settle within a few days, though the timing varies between individuals. Retatrutide has a long half-life, estimated at approximately six days based on phase 2 pharmacokinetic data (Jastreboff et al., NEJM 2023), meaning that drug levels rise gradually and remain relatively stable between weekly doses once a steady state is achieved, typically after approximately four to five weeks of weekly dosing.^[1][2] This gradual accumulation is one reason why titration decisions are made over several weeks rather than days.

During the first week, you may begin to notice a reduction in appetite and food cravings. This is one of the earliest therapeutic signals and reflects the drug's central and peripheral effects on hunger-regulating pathways. It is important not to interpret reduced appetite as a reason to skip meals entirely; maintaining adequate nutrition, including sufficient protein and micronutrient intake, remains important throughout treatment.

Over the first four to eight weeks, your clinical team will monitor you according to the trial protocol schedule. This typically includes, as examples:

• Body weight, to assess early response to treatment

• Blood glucose levels, particularly if you have type 2 diabetes or are taking glucose-lowering medicines

• Renal and hepatic function, as part of routine safety monitoring

• Gastrointestinal symptom burden, to determine whether dose escalation can proceed as planned

The specific assessments and their timing will be set out in your trial protocol and participant information sheet.

If side effects remain troublesome beyond the first week, your clinician may delay dose escalation or provide additional supportive measures. It is important to attend all scheduled follow-up appointments and to contact your trial team promptly if you experience any unexpected or worsening symptoms.

Based on phase 2 trial data (Jastreboff et al., NEJM 2023), meaningful weight loss typically becomes apparent from weeks four to eight onwards, with continued progress over several months at higher doses, though individual responses vary. These findings remain investigational pending the completion of phase 3 trials and regulatory review. Patience and consistent engagement with your healthcare team are central to achieving the best possible outcomes from retatrutide treatment.

Frequently Asked Questions